Last reviewed · How we verify
Myambutol (ETHAMBUTOL)
Myambutol (ETHAMBUTOL) is a small molecule antimycobacterial drug originally developed by STI Pharma LLC and currently owned by Kanchan Hlthcare. It targets the Cytochrome P450 3A4 enzyme and is used to treat acute and pulmonary tuberculosis. Myambutol was FDA approved in 1967 and is now off-patent, with multiple generic manufacturers available. It has a half-life of 3.1 hours and bioavailability of 77%. Key safety considerations include the risk of optic neuritis, particularly at higher doses.
At a glance
| Generic name | ETHAMBUTOL |
|---|---|
| Sponsor | Kanchan Hlthcare |
| Drug class | Antimycobacterial |
| Target | Cytochrome P450 3A4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Acute tuberculosis
- Pulmonary tuberculosis
Common side effects
- Visual acuity decrease
- Nausea
- Vomiting
- Gastrointestinal upset
- Abdominal pain
- Fever
- Malaise
- Headache
- Dizziness
- Mental confusion
- Disorientation
- Possible hallucinations
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myambutol CI brief — competitive landscape report
- Myambutol updates RSS · CI watch RSS
- Kanchan Hlthcare portfolio CI